iCaspase9-transduced T cells

Phase 1Biologic

BBaylor College of Medicine

iCaspase9-transduced T cells is one of 69 biologic programs targeting Suicide. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SuicideActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

SuicidePhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

408 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

40 2

Blincyto

Amgen

Phase 3

45 3

Oncovin

EEastern Cooperative Oncology Group

Phase 3

78 4

Elspar

DDutch Childhood Oncology Group

Phase 3

47 5

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

44 6

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 7

Zyloprim

Alnylam Pharmaceuticals

Phase 3

14 8

Iclusig

Takeda

Phase 3

14 9

Medrol

Pfizer

Phase 3

13 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Active, not recruiting

Acute Lymphoblastic Leukemia

NCT01494103

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene

Active, not recruiting·BBaylor College of Medicine·Phase 1·NCT01494103·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iCaspase9-transduced T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iCaspase9-transduced T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iCaspase9-transduced T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBaylor College of Medicine

iCaspase9-transduced T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News